These behavioral and biochemical findings strongly suggest the identification of spinal IL-17 and CXCL1 cascades in persistent pain development following nerve damage and bone cancer, pointing to the possibility that mitigating astrocyte-mediated neuroinflammatory cascades may provide a promising neuro-therapeutic avenue for chronic nociception states. This evidence concerns the gene IL17A and bone neoplasm.